Liver Transplantation With Tregs at UCSF

Liver Transplant Clinical Trial

— LITTMUS-UCSF  

Official title:

A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03654040
• Other study ID #: DAIT ITN074ST
• Secondary ID: UM1AI109565NIAID
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: April 22, 2021
• Est. completion date: March 6, 2023

Study information

• Verified date: April 2024
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.

Description:

The researchers in this study plan to enroll 9 participants. Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 to 500 x 10^6 total cells.

Participants who successfully withdraw from all immunosuppression (IS) will undergo a research biopsy at 52 weeks following IS discontinuation to determine whether they meet the primary efficacy outcome of operational tolerance. Participants determined to be operationally tolerant will be followed until 104 weeks following IS discontinuation. Participants who fail drug withdrawal after 52 weeks but before 104 weeks will be followed until week 104 or 12 weeks after resuming immunosuppression, whichever is longer.

Participants who do not successfully withdraw from all IS will complete 104 weeks of High Intensity Safety Follow-up after failing immunosuppression withdrawal.

*** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network do not recommend the discontinuation of immunosuppressive therapy for recipients of cell, organ, or tissue transplants outside of physician-directed, controlled clinical studies. Discontinuation of prescribed immunosuppressive therapy can result in serious health consequences and should only be performed in certain rare circumstances, upon the recommendation and with the guidance of your health care provider.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 42
• Est. completion date: March 6, 2023
• Est. primary completion date: March 6, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

Eligibility:

Recipient:

• Individuals must meet all of the following criteria to be eligible for this study:

1. Able to understand and provide informed consent

2. End-stage liver disease and listed for a living or deceased-donor primary solitary liver transplant

3. Agreement to use contraception

4. For candidates with a history of hepatitis C virus (HCV), completed treatment for HCV, maintaining a sustained viral response of =24 weeks duration by the day of transplant

5. Positive Epstein-Barr virus (EBV) antibody test, and

6. Immunizations are up-to-date based on the Advisory Committee on Immunization Practices (ACIP) recommendations for individuals with Liver Disease and Adult Vaccination, unless the investigator determines that administering a recommended immunization is not in the patient's best interest.

Living Donor:

• Living donors must meet all of the following criteria to be eligible for this study:

1. Able to understand and provide informed consent

2. Meets site-specific clinical donor eligibility requirements

3. Meets donor eligibility manufacturing requirements within 7 days before or after the blood collection for manufacturing, and

4. Willingness to donate appropriate biologic samples.

Deceased Donor:

Deceased donors must meet the following criteria for their recipients to remain eligible:

1. Meets site-specific clinical donor eligibility requirements and

2. Meets donor eligibility manufacturing requirements.

Note:

• There are several stages to this study.

• Eligibility is evaluated at many time points during the study to assess whether a participant is safe to proceed to the next study stage.

Exclusion Criteria:

Recipient:

• Individuals who meet any of the following criteria will not be eligible for this study:

1. History of previous organ, tissue or cell transplant

2. For cytomegalovirus (CMV) antibody negative recipients, a (CMV) antibody positive donor

3. Known contraindication to cyclophosphamide or mesna

4. Serologic evidence of human immunodeficiency virus (HIV)-1/2 infection

5. The need for chronic anti-coagulation or anti-platelet agents other than aspirin that cannot be safely discontinued for a minimum of 1 week to safely perform a liver biopsy

6. End stage liver disease secondary to autoimmune etiology (autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis) or other contraindications to drug withdrawal

7. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up visit schedule

8. Any condition that, in the opinion of the investigator, may interfere with study compliance

9. History of cardiac disease (ischemic heart disease requiring revascularization, history of or current treatment for dysrhythmia, or evidence of congestive heart failure), unless cleared by a cardiologist

10. Any past or current medical problems, treatments or findings that are not listed above, which, in the opinion of the investigator, may:

• pose additional risks from participation in the study,

• interfere with the candidate's ability to comply with study requirements, or

• impact the quality or interpretation of the data obtained from the study.

• This includes past, present or future enrollment in studies that affect eligibility at the time of everolimus (EVR) conversion

11. History of malignancy or any concomitant malignancy, except:

• hepatocellular carcinoma,

• completely treated in-situ cervical carcinoma, or

• completely treated basal cell carcinoma.

12. Chronic use of systemic glucocorticoids or other immunosuppressives, or biologic immunomodulators.

Living Donor:

• There are no exclusion criteria for living donors.

Deceased Donor:

-There are no exclusion criteria for deceased donors.

Related Conditions & MeSH terms

• Liver Transplant

Intervention

Biological:
• arTreg
Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10^6 total cells. Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes.

Procedure:
• leukapheresis
Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen. Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion.

Drug:
• cyclophosphamide
40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
• mesna
Mesna is administered: Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and In conjunction with the cyclophosphamide, per institutional practice with CTX.
• everolimus
EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is =50 U/L, GGT LFT is = the upper limit of normal or = 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (4)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and Severity of Adverse Events (AEs) Attributed to the Investigational Product, arTreg	AEs will be attributed to alloantigen-reactive Tregs (arTreg) when the AE is reported with possible or related attribution to arTreg.; Grading: According to the NCI Common Terminology Criteria for Adverse Events Manual [NCI-CTCAE version 5.0, published November 27, 2017].	From arTreg infusion through completion of study participation
Primary	Number and Severity of Adverse Events (AEs) Attributed to Supportive Regimen: Leukapheresis, Cyclophosphamide or Mesna	AEs will be attributed to the supportive regimen for this study when the AE is reported with possible or related attribution to leukapheresis, cyclophosphamide, or mesna.; Grading: According to the NCI Common Terminology Criteria for Adverse Events Manual [NCI-CTCAE version 5.0, published November 27, 2017].	From =3 days prior to arTreg infusion through completion of study participation (Up to 3 months)
Primary	Number of Operationally Tolerant Participants	Operational tolerance is defined as: Discontinuation of all immunosuppression (IS) for 52 weeks,; Alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) = 50 U/L for = 2 measurements separated by =1 week in the 6 weeks prior to the liver biopsy at 52 weeks after the last IS dose, and; Liver biopsy at 52 weeks (±4 weeks) after the last IS dose that meets the biopsy criteria for operational tolerance, as assessed by central pathology.	52 (± 4 weeks) after the last dose of immunosuppression
Secondary	Number of Participants Who Develop a Malignancy	The number of participants that are diagnosed with malignancy, any type.	Time of enrollment through completion of study participation (Up to 1.8 years)
Secondary	Incidence of =Grade 3 Infections Following arTreg Infusion	Grading: According to the NCI Common Terminology Criteria for Adverse Events Manual [NCI-CTCAE version 5.0, published November 27, 2017].	From arTreg infusion through completion of study participation
Secondary	Number of Biopsy-Proven Acute Rejection (AR) and/or Clinical Rejection Events at Any Time After Alloantigen-Reactive Tregs (arTreg) Infusion	Definitions: AR: Diagnosed in accordance with Banff global assessment criteria; Clinical Rejection: Participants who are treated empirically based on investigator clinical suspicion in cases where a biopsy is indeterminate or in rare cases, where a biopsy cannot be performed.	From arTreg infusion through completion of study participation
Secondary	Severity of Biopsy-Proven Acute Rejection (AR) and/or Clinical Rejection Events at Any Time After Alloantigen-Reactive Tregs (arTreg) Infusion	Intensity of AR and/or clinical rejection events will be graded.; Definitions: AR: Diagnosed in accordance with Banff global assessment criteria; Clinical Rejection: Participants who are treated empirically based on investigator clinical suspicion in cases where a biopsy is indeterminate or in rare cases, where a biopsy cannot be performed.	From arTreg infusion through completion of study participation
Secondary	Number of Chronic Rejection Events at Any Time After Alloantigen-Reactive Tregs (arTreg) Infusion	Diagnosed in accordance with Banff global assessment criteria.	From arTreg infusion through completion of study participation
Secondary	Proportion of Participants Who Successfully Discontinue Tacrolimus	Proportion of participants who, per protocol: fulfill eligibility for tacrolimus withdrawal,; subsequently achieve their last dose of tacrolimus,; remain tacrolimus-free for =12 weeks,; their liver function tests, ALT and GGT, are =50 U/L,; and their liver biopsy performed between 12 to 26 weeks status post the last dose of tacrolimus fulfills biopsy findings* for minimization of immunosuppression.; Biopsy findings: Liver histology will be assessed by central pathology. Biopsy findings for minimization of immunosuppression, per protocol. Reference: Demetris AJ, Bellamy C, Hubscher SG, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016.	Post-transplant through Completion of Study Participation
Secondary	Duration of Operational Tolerance	Durability of operational tolerance defined as the time from achieving the primary endpoint to immunosuppression (IS) reinitiation or to the end of trial participation.	Post-transplant through Completion of Study Participation

External Links

•   Immune Tolerance Network web site